Neumora Therapeutics, Inc. Common Stock (NASDAQ: NMRA) is a Healthcare company (Biotechnology) with a market capitalization of $63M. The Maz Rating grades it against the other companies in its sector.
Neumora Therapeutics, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $0.33, Neumora Therapeutics, Inc. Common Stock trades at 3621.7x sales and 3.1x book value, with an EV/EBITDA of 0.1. Over the last twelve months it generated about $17354 of revenue and a net loss of $216M. It runs a gross margin of 0.0%, an operating margin of -1168393.8% and a net margin of -1190187.5%. It shows return on equity of -320.6%, return on invested capital of -296.6% and a free cash flow yield of -266.2%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 3.69. Over the past 52 weeks the share price ranged from $0.30 to $3.65, with a beta of 3.14.
Neumora Therapeutics, Inc. Common Stock does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 6 Buy, 1 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.